Cargando…
Investigation of nicotinamide as more than an anti-phosphorus drug in chronic hemodialysis patients: a single-center, double-blind, randomized, placebo-controlled trial
BACKGROUND: Hyperphosphatemia is a common complication of late-stage chronic kidney disease (CKD). Nicotinamide (NAM) has been reported as an adjunctive therapy for hyperphosphatasemia, but the effect of NAM on fibroblast growth factor 23 (FGF23) and Klotho has rarely been reported. METHODS: We rand...
Autores principales: | Liu, Xiang-Yang, Yao, Jing-Rui, Xu, Rong, Xu, Lin-Xin, Zhang, Yue-Feng, Lu, Shan, Xing, Zhi-Heng, Fan, Li-Ping, Qin, Zhong-Hua, Sun, Bei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214904/ https://www.ncbi.nlm.nih.gov/pubmed/32411753 http://dx.doi.org/10.21037/atm.2020.03.228 |
Ejemplares similares
-
Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial
por: Akizawa, Tadao, et al.
Publicado: (2014) -
Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial
por: Gao, Xiangyang, et al.
Publicado: (2023) -
Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: A systematic review and meta-analysis
por: Zhang, Yong, et al.
Publicado: (2018) -
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial
por: Katayoshi, Takeshi, et al.
Publicado: (2023) -
Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
por: Leung, Christopher Kai Shun, et al.
Publicado: (2022)